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ABSTRACT
Cancer arises from loss of function of tumour suppressors and/or gain of function mutations in pro-
to-oncogenes that disrupt the delicate balance required for homeostatic cell division, resulting in 
uncontrolled cell proliferation. Oncogenic transformation of multifaceted proto-oncogene - transcrip-
tion factor - MYC can give rise to cancers and it is found to be deregulated in more than 70% of the 
tumours. Targeting MYC directly or identifying the Achille’s heel of MYC-driven tumours is thus 
a promising therapeutic approach to treat these tumours. This thesis investigates and demonstrates 
novel therapeutic approaches against MYC-driven tumours.
In the first publication (Bhadury et al, 2014), we characterize a novel and orally bio-available BET 
bromodomain inhibitor (BETi) RVX2135. We also identified BET bromodomain proteins as a valu-
able therapeutic target against MYC driven tumours in vitro and in vivo. Gene expression profiling 
to identify these transcriptional changes enabled us to identify subset of genes that are commonly 
altered by both BETi and HDACi. This study also demonstrates that HDACi and BETi can synergize 
to hinder Myc-induced lymphoma progression.
The second publication (Muralidharan et al, 2016) in this thesis investigates the role of BET proteins 
in regulating cell cycle and replication. BETi disable the entry of cells into S-phase of cell-cycle, ham-
per DNA synthesis and cause DNA damage. A pharmacogenetic screen identified BET inhibitors to 
synergize with inhibition of PI3K/mTOR family of proteins, to which ATR, an upstream kinase of 
DDR pathway belongs. Further studies revealed that the thus identified PI3K/mTOR inhibitors indeed 
affect ATR-Chkl DDR pathway leading to the discovery of a strong synergy between BETi and ATRi 
in apoptosing Myc driven tumours in vitro, and in vivo and (by) it induces SASP and ER stress.
The third study translates the above findings into the field of melanoma, a form of skin cancer. We 
validate the BETi-ATRi synergy in cell lines in vitro and in Patient Derived Xenografts (PDX) in 
vivo. Using B16F10 in vivo syngenic transplant melanoma model, we also demonstrated that this 
combination therapy can be safely combined with Immune Therapy, the front line treatment against 
melanoma in clinic today.
Taken together, this thesis puts forth a multifaceted approach to treat cancer. It thoroughly describes 
the effects of BETi and ATRi on cancer cells and how they can be combined to enhance the therapeutic 
efficacy.
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